KNSA - Kiniksa Pharmaceuticals Interna

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare cardiovascular and inflammatory diseases, with its primary approved product being Arcalyst (rilonacept), an IL-1 blocker indicated for recurrent pericarditis (inflammation of the heart sac). The company sells Arcalyst directly to specialty pharmacies and healthcare providers treating patients with this rare condition, operating a specialty pharmaceutical business model with high per-patient revenue and a concentrated prescriber base. Kiniksa generates approximately $150-200M in annual net product revenue, with its commercial operations centered primarily in the United States. The company also has a pipeline of investigational assets targeting additional inflammatory and cardiovascular indications.

Past Year Trends

• ARCALYST net product revenue grew 62% year-over-year to $677.6 million in FY2025, driven by continued expansion in recurrent pericarditis patients, enabling a profitability flip from a $43.2 million net loss in 2024 to $59.0 million net income in 2025. (Bullish)
• Kiniksa discontinued development of abiprubart for Sjögren's Disease in February 2025 after Phase 2b enrollment, narrowing the pipeline and eliminating a potential diversification asset, with the company now exploring strategic alternatives for this asset. (Bearish)
• Cash and short-term investments grew from approximately $268 million at the start of 2025 to $468.1 million by Q1 2026, funded by $137.985 million in operating cash flow in FY2025 and $50.2 million in Q1 2026. (Bullish)

Next Year Trends

• KPL-387 Phase 2 data in recurrent pericarditis is expected in 2H 2026, representing the company's primary pipeline read-out; a positive result could validate the next growth leg beyond ARCALYST, while failure would leave the company single-product dependent. (Bullish)
• Full-year 2026 ARCALYST revenue guidance was raised to $930–945 million after Q1 2026 results of $214.3 million (+56% YoY), implying approximately 37–40% full-year growth, but any slowdown in new patient starts or payer pushback on pricing would pressure this guidance. (Bullish)
• Collaboration expenses surged to $75.6 million in Q1 2026 versus $43.8 million in Q1 2025 due to ARCALYST profit-share obligations, and continued revenue growth will mechanically drive these costs higher, compressing net income margins even as top-line expands. (Bearish)

Red Flags

No severe red flags identified as of August 2025.